Firsthand Technology Value Fund Inc Stock Price, News & Analysis

Firsthand Technology Value Fund (SVVC) reported its top five investments as of October 31, 2022. These holdings represent 95.4% of the Fund's estimated total investments, valued at approximately $46.8 million or $6.78 per share, including cash equivalents of $0.13 per share. The largest investment is in IntraOp Medical (44.3%), followed by Wrightspeed (25.8%), Hera Systems (15.6%), Revasum (7.1%), and EQX Capital (2.6%). A full financial report will be published in March 2023.

Firsthand Technology Value Fund (NASDAQ: SVVC) reported its third-quarter results for 2022, showing significant declines in net assets and investment performance. As of September 30, 2022, net assets decreased to approximately $38.4 million from $49.8 million in June. The fund recorded a total investment loss of around $8.3 million and a net investment loss of about $8.8 million. The fair value of the portfolio was approximately $46.6 million, translating to $6.76 per share, with cash and equivalents of $1.15 million.

Firsthand Technology Value Fund (NASDAQ: SVVC) announced its preliminary NAV of $5.58 as of September 30, 2022. The Fund's top five holdings included IntraOp Medical (54.0% of net assets), Wrightspeed (31.1%), Hera Systems (19.0%), Revasum (7.9%), and EQX Capital (3.1%). Total investments were reported at $46.6 million, or $6.76 per share. Notably, these top holdings made up 115.1% of the Fund’s preliminary net assets. The complete financial statements will be available in the upcoming quarterly report due in November 2022.

Firsthand Technology Value Fund (NASDAQ: SVVC) reported its top five investments as of August 31, 2022, totaling approximately $47 million, or $6.82 per share. These holdings, which include IntraOp Medical Corp., Wrightspeed, Hera Systems, Revasum, and EQX Capital, account for 93.7% of its total investments. IntraOp Medical represents 34.8%, while Wrightspeed follows closely at 34.1%. A detailed financial report will be released in November 2022, outlining performance metrics and changes since June 30, 2022.

As of July 31, 2022, Firsthand Technology Value Fund (NASDAQ: SVVC) reported its top five holdings, representing 93.2% of estimated total investments of approximately $50.2 million, or $7.28 per share. Key holdings include:

• IntraOp Medical (32.6%)
• Wrightspeed (31.4%)
• Revasum (15.8%)
• Hera Systems (11.2%)
• EQX Capital (2.3%)

The Fund focuses on investments in technology and cleantech companies.

Firsthand Technology Value Fund (NASDAQ: SVVC) announced that Hera Systems, a holding since 2015, will provide spacecraft for the U.S. Space Force's Tetra-5 program. This program aims to develop a prototype constellation for on-orbit refueling and autonomous collaboration. The contract, awarded to Orion Space Solutions, could total $44.5 million if fully exercised. Hera Systems will deliver advanced spacecraft and software for the mission.

Firsthand Technology Value Fund (NASDAQ: SVVC) reported its financial results for Q2 2022, revealing net assets of approximately $49.8 million or $7.22 per share, down from $87.4 million or $12.68 per share as of March 31, 2022. The Fund's total investment loss was about $3.8 million, leading to a net investment loss of approximately $4.5 million. Realized and unrealized losses on investments reached $33.1 million during the quarter. The Fund continues to manage its portfolio actively to enhance performance.

Firsthand Technology Value Fund (NASDAQ: SVVC) reported a preliminary NAV of $7.22 as of June 30, 2022. The Fund's top five holdings—IntraOp Medical, Wrightspeed, Revasum, Hera Systems, and Pivotal Systems—constitute 92.4% of its net assets. IntraOp Medical leads with 32.8% of net assets, while Wrightspeed follows with 30.7%. Total investments stood at $49.3 million or $7.16 per share. The complete financials will be part of the quarterly report in August 2022.

As of May 31, 2022, Firsthand Technology Value Fund (NASDAQ: SVVC) reported its top five holdings, which comprise 92.4% of its estimated total investments of approximately $66.8 million. These include IntraOp Medical (32.2%), Wrightspeed (28.5%), Revasum (17.5%), Hera Systems (9.4%), and Pivotal Systems (4.9%). The Fund's estimated value per share stands at $9.70, with cash and equivalents at approximately $0.27 per share. A comprehensive financial report will be available in August 2022.